| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9c820725f89c0315e7d534fadb13aabc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e7d3e420ebf9711c4207b425bc01547 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3521
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3231 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02 |
| filingDate |
2013-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f80df63d0ee51dba5bb4dcf9f144f352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0a91fc9b51bfca5b35661de277720a4 |
| publicationDate |
2015-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9217147-B2 |
| titleOfInvention |
Spinal muscular atrophy treatment via targeting SMN2 catalytic core |
| abstract |
The present invention is directed to methods and compositions for blocking the effect of the intronic inhibitory splicing region of intron 7 of the SMN2 gene. The compositions and methods of the instant invention include short oligonucleotide reagents (e.g., oligoribonucleotides) that effectively target sites in the SMN2 pre-mRNA, thereby modulating the splicing of SMN2 pre-mRNA to include exon 7 in the processed transcript. The short target regions are 8-mers and 5-mers and also include the identification of a single nucleotide base that is essential for initiating a long distance stearic inhibitory interactions as well as novel targets distant from intron 7 which block the intronic inhibitory splicing of the same. These short target regions and concomitant inhibitory blocking oligonucleotides are less expensive and easier to manufacture and are small enough to cross the blood brain barrier. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10538764-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10941405-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10696969-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10266822-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11096956-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11083745-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11702660-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10913947-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11299737-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10683503-B2 |
| priorityDate |
2010-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |